Zana Technologies GmbH
Zana Technologies uses voice and AI to support better health outcomes through digital health companions and advanced voice-based diagnostics.
Classification
Profile
Funding
Zana uses voice and AI to support better health outcomes through digital health companions and advanced voice-based diagnostics.
Healthcare industry buyers in the DACH region utilizing digital health platforms and voice data analysis.
SaaS/API licensing
Direct Sales Force - enterprise account executives targeting pharma & large health systems · Strategic Partnerships - integration partners (EHR vendors, telehealth platforms) that embed Zana’s SDK · Industry Conferences & Digital Health Accelerators - showcase at MedTech Europe, HIMSS, and EU-Startups events
University Clinics & Research Institutes - for clinical validation and data access · EHR & Telehealth Vendors - (e.g., Cerner, Teladoc) to embed the companion · Pharma Sponsors - co-development of disease-specific modules
R&D and deep tech development for AI-driven voice analysis solutions.
Proprietary AI technology leveraging voice data as a biological marker for health assessment.
Developing digital health companions and advanced voice-based diagnostic tools using voice and AI.
Dedicated Account Management - for pharma/health-system contracts (onboarding, KPI tracking) · Technical Success Teams - ensure integration, compliance, and continuous performance monitoring · Community & Patient Support - in-app chat, AI-coach, and moderated forums to boost patient adherence
Competes in the voice biomarker and digital health space with other AI diagnostics firms; differentiates through validated digital patient companions and specific focus on voice as a biological marker rather than just speech-to-text.
Need for better health outcomes and advanced diagnostic methods beyond traditional biological markers.
Diversify disease focus to broaden TAM · Introduce outcome-based pricing to align incentives and increase contract size · Build deeper integration with EHR/telehealth platforms to become a “plug-and-play” solution
Zana's proprietary voice-as-biomarker technology creates a defensible moat by combining deep tech IP with clinical validation from university partners.
Strategic partnerships with EHR vendors enable direct channel access to enterprise buyers, facilitating the SaaS revenue model through embedded SDKs.
The company’s CE-marked status and GDPR compliance are rare among early-stage health-AI startups, providing a strong regulatory moat · Partnerships with reputable university clinics validate the clinical credibility of the voice-biomarker technology
No investors recorded yet.